Agilent Technologies (A) Expected to Announce Quarterly Earnings on Wednesday

Agilent Technologies (NYSE:A) is projected to issue its Q3 2025 results after the market closes on Wednesday, August 27th. Analysts expect the company to announce earnings of $1.37 per share and revenue of $1.6660 billion for the quarter. Agilent Technologies has set its FY 2025 guidance at 5.540-5.610 EPS. Q3 2025 guidance at 1.350-1.370 EPS.Parties can check the company’s upcoming Q3 2025 earningsummary page for the latest details on the call scheduled for Wednesday, August 27, 2025 at 4:30 PM ET.

Agilent Technologies (NYSE:A) last posted its quarterly earnings results on Wednesday, May 28th. The medical research company reported $1.31 EPS for the quarter, topping analysts’ consensus estimates of $1.26 by $0.05. The business had revenue of $1.67 billion during the quarter, compared to the consensus estimate of $1.63 billion. Agilent Technologies had a return on equity of 25.92% and a net margin of 17.59%.The company’s revenue for the quarter was up 6.0% compared to the same quarter last year. During the same period last year, the firm earned $1.22 earnings per share. On average, analysts expect Agilent Technologies to post $6 EPS for the current fiscal year and $6 EPS for the next fiscal year.

Agilent Technologies Stock Up 1.7%

NYSE:A opened at $120.1460 on Wednesday. The company has a market capitalization of $34.13 billion, a price-to-earnings ratio of 29.67, a price-to-earnings-growth ratio of 3.58 and a beta of 1.22. Agilent Technologies has a one year low of $96.43 and a one year high of $153.84. The stock has a 50-day simple moving average of $117.84 and a 200 day simple moving average of $117.86. The company has a debt-to-equity ratio of 0.55, a quick ratio of 1.60 and a current ratio of 2.09.

Agilent Technologies Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Wednesday, July 23rd. Investors of record on Tuesday, July 1st were paid a $0.248 dividend. This represents a $0.99 dividend on an annualized basis and a yield of 0.8%. The ex-dividend date was Tuesday, July 1st. Agilent Technologies’s dividend payout ratio (DPR) is 24.44%.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on A shares. JPMorgan Chase & Co. decreased their price target on Agilent Technologies from $160.00 to $155.00 and set an “overweight” rating for the company in a research note on Thursday, May 29th. UBS Group dropped their target price on shares of Agilent Technologies from $150.00 to $130.00 and set a “neutral” rating on the stock in a report on Thursday, May 29th. Wall Street Zen raised shares of Agilent Technologies from a “hold” rating to a “buy” rating in a report on Saturday, June 28th. Evercore ISI increased their target price on shares of Agilent Technologies from $125.00 to $130.00 and gave the stock an “in-line” rating in a report on Tuesday, July 8th. Finally, Robert W. Baird dropped their target price on shares of Agilent Technologies from $159.00 to $140.00 and set an “outperform” rating on the stock in a report on Thursday, May 22nd. Seven analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $139.77.

Insider Transactions at Agilent Technologies

In other Agilent Technologies news, CEO Padraig Mcdonnell sold 1,508 shares of the firm’s stock in a transaction dated Tuesday, July 1st. The shares were sold at an average price of $117.44, for a total value of $177,099.52. Following the transaction, the chief executive officer owned 37,448 shares of the company’s stock, valued at $4,397,893.12. This trade represents a 3.87% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. 0.26% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Agilent Technologies

Large investors have recently made changes to their positions in the company. Brighton Jones LLC increased its stake in shares of Agilent Technologies by 6.1% in the fourth quarter. Brighton Jones LLC now owns 4,663 shares of the medical research company’s stock valued at $626,000 after purchasing an additional 270 shares during the period. Diversify Advisory Services LLC acquired a new stake in shares of Agilent Technologies in the second quarter valued at approximately $670,000. Acadian Asset Management LLC increased its stake in shares of Agilent Technologies by 16.5% in the first quarter. Acadian Asset Management LLC now owns 5,352 shares of the medical research company’s stock valued at $625,000 after purchasing an additional 758 shares during the period. Jones Financial Companies Lllp boosted its holdings in shares of Agilent Technologies by 15.9% in the first quarter. Jones Financial Companies Lllp now owns 5,610 shares of the medical research company’s stock valued at $602,000 after acquiring an additional 769 shares in the last quarter. Finally, Brevan Howard Capital Management LP bought a new position in shares of Agilent Technologies in the second quarter valued at approximately $482,000. Institutional investors and hedge funds own 87.41% of the company’s stock.

About Agilent Technologies

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.